New Study of Option Care Data Suggests Improved Survival for Heart Failure Patients Receiving Home Infusion of Inotropic Therapy When Coupled with Guideline-Directed Medical Therapy
BANNOCKBURN, Ill.--(BUSINESS WIRE)--May 16, 2018--Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently published in The Journal of Heart and Lung Transplantation. 1 The study was conducted by investigators from Keck School of Medicine of USC and Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate treatment site infusion services.
Patients with advanced heart failure (Stage D) may be prescribed intravenous (IV) inotropic therapy while they await a heart transplant or mechanical circulatory support, or as a palliative measure. The therapy may improve quality of life 2 by enabling patients’ hearts to pump more efficiently, which may increase their energy levels and may help them breathe easier. While previous research found that patients receiving inotropic therapy survived an average of three to six months, the study of Option Care data suggests an average survival of more than two years. 3,4 Additionally, survival is improved when doctors follow American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guideline recommendations for delivering the therapy, which includes prescribing other medications such as beta blockers.
“Advanced heart failure patients suffer from extreme fatigue and poor quality of life. Inotropic therapy can make a big difference in their lives, helping them get back to the day-to-day activities that many of us take for granted, such as enjoying time with family,” said Luanda P. Grazette, MD, MPH, principal investigator of the study and associate professor of clinical medicine at the Keck School of Medicine of USC. “As doctors, we sometimes avoid inotropic therapy out of concerns about decreasing survival. Through this research we found that survival on inotropes has improved quite a bit compared to what was observed from studies in the late 1990s and early 2000s. In this study it was not unusual for many patients to live for years on this therapy. This was quite a surprise.”
“Receiving this life-changing therapy in the comfort of home helps patients more fully enjoy their lives,” said Tess Artig-Brown, BSN, MN, co-author of the study and director of Option Care’s Heart Failure Program. “Patients are able to spend more time at home surrounded by family rather than in a hospital or long-term care center where they may be exposed to antibiotic-resistant infections. Home infusion is also much more cost effective than care provided in the hospital or long-term care centers and research has shown that with education and support, these patients are less likely to be readmitted to the hospital. 5 ”
Presented recently at the 38 th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation in Nice, France, the study is the largest to date to focus on long-term use of inotropic therapy.
The study included 3,296 advanced heart failure patients treated with inotropes between May 2009 and June 2016. The overall adjusted median survival on continuous inotrope therapy was 771 days. The average time on inotrope therapy was 171.2 days with a minimum of one day and a maximum of 2,204 days. The majority of patients, 2,300 (69.8 percent), were treated with milrinone, 942 (28.6 percent) with dobutamine and 54 (1.6 percent) received dopamine. Beta blocker therapy, used by 799 patients (24.2 percent), reduced mortality by 50 percent.
Earlier studies reported a higher mortality rate among patients on inotropic therapy, but they were conducted when the treatment practices were different, including bolusing (providing a large initial dose) – which has since been determined to be too taxing for the heart – followed by continuous infusion at much higher doses than what is currently used. Most physicians now start patients on the lowest dose and increase it slowly to achieve the desired result. The guidelines note it’s important that prior to advancing to Stage D, heart failure patients are prescribed oral and mechanical therapies as appropriate, such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors or implantable cardioverter defibrillators (ICDs).
About Option Care
Option Care Enterprises, Inc. (Option Care) is the nation’s largest and most trusted provider of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians – including pharmacists, nurses and dietitians – are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.Havakuk O, Tran J, Artig-Brown T, et al. Intravenous inotropes, beta blockers and survival in ambulatory heart failure patients – a contemporary study in 3,311 patients. J Heart Lung Transplant. 2018;37(4)(suppl):S202. Walther K, Artig-Brown T, et al. The impact of home infusion on quality of life in patients with heart failure receiving home inotropic therapy based on the Minnesota Living With Heart Failure Questionnaire. Poster presented at the 2017 National Home Infusion Association (NHIA) Annual Conference & Exposition: May 22-25, 2017; Orlando, Fla. Hauptman PJ, Mikolajczak P, George A, Mohr et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J. 2006;152:1096 e1-8. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-7. Meaux N. and Tatiel M. Hospital admission reductions among Stage D heart failure patients participating in a home inotropic infusion program. Poster presented at 7 th Annual Meeting of the American Association of Heart Failure Nurses (AAHFN): June 23-25, 2011; Seattle.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005961/en/
CONTACT: For Option Care
Media Contact Information:
KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS
INDUSTRY KEYWORD: HEALTH CARDIOLOGY CLINICAL TRIALS HOSPITALS PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE MANAGED CARE
SOURCE: Option Care Enterprises, Inc.
Copyright Business Wire 2018.
PUB: 05/16/2018 10:56 AM/DISC: 05/16/2018 10:56 AM